EGFR and neoplasm: Mechanistically, the antibodies simultaneously engage EGFR/ERBB2 on tumor cells and the NKG2D-CAR on NK cells, establishing close-range immune synapses that directly activate CAR-NK cells irrespective of endogenous NKG2D-ligand expression, thereby overcoming target-recognition loss 81.